Bristol-Myers Squibb Services Unlimited Company: clinical-trial pipeline
Bristol-Myers Squibb Services Unlimited Company is the sponsor of 2,023 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 227 are not yet finished and 10 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials227
Phase 2/3 and 3372
Countries76
New in 90 days10
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 662 |
| Phase 2 | 399 |
| Not applicable | 390 |
| Phase 3 | 338 |
| Phase 1/2 | 145 |
| Phase 4 | 54 |
| Phase 2/3 | 34 |
| Early phase 1 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,511 |
| Terminated | 215 |
| Recruiting | 105 |
| Active, not recruiting | 93 |
| Withdrawn or not authorised | 66 |
| Not yet recruiting | 29 |
| Unknown | 3 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 968 |
| Gastroenterology and liver | 269 |
| Infectious disease and vaccines | 245 |
| Immunology and rheumatology | 242 |
| Cardiovascular | 163 |
| Rare and genetic diseases | 120 |
| Nephrology and urology | 113 |
| Dermatology | 72 |
| Haematology | 65 |
| Neurology | 56 |
| Metabolic and endocrine (diabetes, obesity) | 44 |
| Psychiatry and mental health | 35 |
Countries
| Country | Trials |
|---|---|
| United States | 1,412 |
| Spain | 527 |
| France | 525 |
| Canada | 501 |
| Italy | 488 |
| Germany | 469 |
| United Kingdom | 409 |
| Australia | 376 |
| Poland | 311 |
| Japan | 294 |
| Belgium | 292 |
| Netherlands | 249 |
| Argentina | 234 |
| South Korea | 222 |
| Austria | 199 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-21 | New trial posted | A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Health… |
| 2026-10-14 | New trial posted | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases |
| 2026-10-13 | New trial posted | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Bef… |
| 2026-10-01 | New trial posted | First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain |
| 2026-10-01 | New trial posted | Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in He… |
| 2026-09-29 | New trial posted | Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic C… |
| 2026-09-24 | New trial posted | [14C]Navlimetostat Mass Balance Study in Healthy Female Participants |
| 2026-09-23 | New trial posted | A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess… |
| 2026-09-02 | New trial posted | A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Partic… |
| 2026-08-27 | New trial posted | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Complet… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05076175 | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcera… | Phase 2/3 | Recruiting | Australia, Belgium, Canada, Germany +9 |
| NCT06122779 | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failu… | Phase 2 | Active, not recruiting | Argentina, Canada, China, Spain +7 |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma | Phase 2/3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
| NCT06253221 | A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active, not recruiting | Australia, Canada, Germany, Spain +5 |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other… | Phase 1/2 | Active, not recruiting | Canada, Spain, United Kingdom, Norway +1 |
| 2023-503697-21-01 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety,… | Phase 3 | Not yet recruiting | Austria, Belgium, Czechia, Germany +11 |
| NCT04245839 | A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent… | Phase 2 | Active, not recruiting | Austria, Canada, Germany, Spain +6 |
| NCT03899155 | Pan Tumor Rollover Study | Phase 2 | Recruiting | Argentina, Austria, Australia, Belgium +33 |
| NCT06025578 | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pul… | Phase 3 | Not yet recruiting | Argentina, Austria, Australia, Belgium +30 |
| NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and De… | Phase 3 | Recruiting | Argentina, Austria, Australia, Belgium +24 |
| NCT03989414 | A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of… | Phase 1/2 | Active, not recruiting | Canada, Czechia, Germany, Denmark +5 |
| 2024-510799-19-00 | A Phase 1b/2a Multicenter, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess… | Phase 1/2 | Active, not recruiting | Germany, Spain, France, Italy +1 |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participan… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Bulgaria +33 |
| NCT02677922 | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Target… | Phase 1/2 | Active, not recruiting | Australia, Belgium, Canada, Switzerland +10 |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear… | Phase 3 | Active, not recruiting | Argentina, Brazil, Chile, Czechia +12 |
| 2024-510800-35-00 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamet… | Phase 3 | Active, not recruiting | Austria, Belgium, Czechia, Germany +12 |
| NCT06268886 | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446)… | Phase 2 | Active, not recruiting | Australia, Belgium, Canada, Spain +6 |
| NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents… | Phase 3 | Not yet recruiting | Australia, Spain, Italy, Mexico +6 |
| NCT03930953 | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Pa… | Phase 1/2 | Active, not recruiting | Argentina, Austria, Belgium, Brazil +11 |
| NCT06425302 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With… | Phase 2 | Active, not recruiting | Australia, Brazil, Canada, Chile +9 |
| 2024-515518-41-00 | [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion | Phase 1 | Recruiting | Spain, Hungary |
| NCT06869551 | A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Partic… | Phase 3 | Recruiting | Bulgaria, Brazil, China, Czechia +6 |
| NCT06646276 | A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Co… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combination… | Phase 1/2 | Recruiting | Australia, Canada, Chile, Spain +6 |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Parti… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Brazil +22 |
Hiring for clinical development
Bristol-Myers Squibb Services Unlimited Company has 67 open jobs with a clinical, regulatory, safety, biostatistics or medical-affairs title on its own career sites.
Website: bms.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Bristol-Myers Squibb Services Unlimited Company clinical trials: 227 open, 372 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/bms-com/, data as of 2026-10-25.